Friday, September 11, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Sep 10, 2026
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
background ▾
- •Del-desiran failure from $12B Avidity deal triggered 10%+ stock decline and $30B market cap loss, sparking shareholder activism on M&A governance.
- •Major investor is demanding board-level changes to dealmaking processes and has flagged three troubled acquisitions (Avidity, MorphoSys, Ionis stake) as evidence of poor deal vetting.
- •Watch for: Board composition changes, tightened M&A approval frameworks, further clinical data on pelabresib (MorphoSys asset with safety signal), and investor pressure at next shareholder meeting.
NovartisArtisan PartnersAvidity Biosciencesdel-desiranpelacarsenpelabresib
→ Read original articlePolicy•Fierce Biotech•Sep 10, 2026
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
background ▾
- •Takeda's R&D leadership transition occurs at a pivotal moment as the company faces LOE on blockbuster Entyvio and must sustain momentum from recent approvals (Orzeyful, Mimrylo, Livtencity, Adzynma, Eohilia) and zasocitinib advancement
TakedaSanofiGammaDelta TherapeuticsVyvanseOrzeyfulMimrylo
→ Read original articlePolicy•Fierce Biotech•Sep 11, 2026
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
background ▾
- •De Claro is the first senior FDA drug evaluation leader to be permanently confirmed under the Trump administration, providing regulatory stability to the OCE during organizational turnover
- •The new OCE director plans to integrate AI tools into regulatory reviews and expand the Real-Time Oncology Review (RTOR) framework to accelerate approvals, as demonstrated by the accelerated Rasonque review
- •Watch for implementation of AI-assisted review processes and whether de Claro can maintain the OCE's innovation track record while managing staff retention challenges during the broader FDA leadership transition
Revolution MedicinesFDARasonque (daraxonrasib)
→ Read original articlePolicy•STAT News•Sep 11, 2026
Opinion: I’m a public health communications consultant. Pro-vaccine advocacy needs more fun
background ▾
- •Pro-vaccine communication strategy has shifted from celebration and movement-building to defensive fact-checking and somber expert messaging, undermining public engagement
polio vaccineflu vaccineCovid-19 vaccine
→ Read original articlePolicy•STAT News•Sep 11, 2026
Opinion: I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over
background ▾
- •This is an opinion/editorial piece without clinical trial data, regulatory decisions, or industry-specific pharmaceutical news
Market Access
Market Access•Fierce Biotech•Sep 10, 2026
Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs
background ▾
- •Frazier Life Sciences has raised $1.1 billion for its public biotech fund, demonstrating sustained LP confidence in life sciences investing despite market volatility
Frazier Life SciencesMerck & Co.Vertex Pharmaceuticals
→ Read original articleMarket Access•Endpoints News•Sep 10, 2026
Lonza to build new US factory; Samsung Bio signs $262M contract
background ▾
- •Lonza is expanding US contract manufacturing capacity, indicating strong market demand for CDMO services and potential supply chain constraints in the industry
- •Samsung Bioepis' $262M contract win demonstrates competitive activity in the contract manufacturing space and validates biosimilar/biologic production capabilities
LonzaSamsung Bioepis
→ Read original articleMarket Access•Endpoints News•Sep 10, 2026
How past Endpoints 11 winners fared as biotech industry rebounded
background ▾
- •Endpoints News Endpoints 11 awards event scheduled for September 24 in Boston
Market Access•Endpoints News•Sep 10, 2026
What Oura's IPO filing reveals about its healthcare ambitions
background ▾
- •Oura's IPO filing signals intent to pursue deeper healthcare integration beyond consumer wearables, though specific pharma partnerships or clinical applications remain undisclosed
Oura Health
→ Read original articleMarket Access•Endpoints News•Sep 9, 2026
Encoded closes $275M Series F for Dravet syndrome drug
background ▾
- •Encoded raised $275M Series F led by GV, indicating strong investor backing for its Dravet syndrome program and broader pipeline
- •Funding timing and use of proceeds suggest the company is preparing for advanced clinical development or regulatory submissions in rare neurological indications
Encoded TherapeuticsGVDravet syndrome therapy (program)
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 10, 2026
Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal
background ▾
- •FDA partial clinical hold on BHV-7000 enrollment triggered by rodent metabolite findings of unknown human relevance, occurring within days of the $350M SK Biopharmaceuticals licensing agreement
- •Hold is partial: allows treatment continuation and one pivotal trial data readout this year, but blocks new enrollment pending nonclinical risk characterization expected within weeks
- •SK and Biohaven committed to proceeding with the deal and generating metabolite safety data; the outcome will depend critically on whether nonclinical findings prove translatable to human risk
BiohavenSK BiopharmaceuticalsKnopp BiosciencesBHV-7000opakalim
→ Read original articleClinical Trials•Endpoints News•Sep 10, 2026
Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label
background ▾
- •Shionogi's stroke drug failed in mid-stage development, eliminating a pipeline asset and raising questions about the company's neurology strategy
- •Bayer's Hyrnuo label expansion improves market positioning and potential revenue runway for the asset
ShionogiBayerTevard BiosciencesHyrnuoMimrylo
→ Read original articleClinical Trials•STAT News•Sep 10, 2026
Platinum-based chemotherapy in childhood causes mutations that age the liver
background ▾
- •Platinum-based chemotherapy induces an average of 2,200 mutations per liver sample in treated children, prematurely aging liver cells to adult-level mutation burdens, with mutation load correlating directly to cumulative platinum exposure
- •Liver tissue accumulates significantly more mutations than blood cells despite systemic chemotherapy delivery, suggesting differential metabolism or DNA repair mechanisms in hepatic tissue that warrant mechanistic investigation
- •The finding supports long-term survivorship studies extending beyond the third decade of life and may catalyze development of next-generation platinum analogues with improved therapeutic selectivity to minimize off-target mutagenesis
cisplatincarboplatin
→ Read original articleClinical Trials•STAT News•Sep 10, 2026
Why two promising heart drugs flopped and what’s next
background ▾
- •Two large, well-funded clinical trials from major pharma players (Novo Nordisk and Novartis) in heart disease have failed, representing significant setbacks for the cardiovascular pipeline
- •Industry investment and earlier promise were insufficient to translate into positive trial outcomes, raising questions about target validation and trial design in cardiology
- •The failures may reshape how companies approach heart disease drug development and prioritize future cardiovascular programs
Novo NordiskNovartisMerck
→ Read original articleClinical Trials•Endpoints News•Sep 10, 2026
BridgeBio Oncology slides as it tightens the scope of its KRAS program
background ▾
- •BridgeBio Oncology is scaling back the scope of its KRAS-targeted program, prompting substantial shareholder sell-off
- •The market interpreted this as a negative development for the program's prospects or the company's oncology pipeline trajectory
BridgeBio Oncology TherapeuticsKRAS inhibitor (program name/INN not specified)
→ Read original article